Please assess the completion status of the following clinical trial:

Trial Title: EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Capable of giving informed consent~2. Stated willingness to comply with all study procedures and availability for the duration of the study~3. Male or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyes~Exclusion Criteria:~1. Current or past diagnosis of endophthalmitis~2. Current diagnosis of uveitis~3. Current use of viscous lidocaine products for ocular anesthesia prior to IVT~4. Currently receiving intravitreal steroid injections~5. Concurrent participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test Drug (Type: EXPERIMENTAL): IRX-101 drops instilled prior to intravitreal injection
- Control (Type: ACTIVE_COMPARATOR): Povidone-Iodine/Betadine drops instilled prior to intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).